Pure Global
NCT05143736

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients

Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Patients With Sepsis: a Prospective, Multicentered, Diagnostic Trial
Zhujiang Hospital·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Sepsis,Septic Shock
Drug/Device/Intervention
gut and nasal microbiota detection
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Zhujiang Hospital
Location
Dongguan,Guanzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jan 10, 2022
End date
Jan 31, 2023
Enrollment
300 participants
Primary outcome

All-cause death at 28 days

Summary

In this prospective, multicentered , diagnostic trial, nasal and fecal specimens will
 collected from patients with sepsis in two critical care units(ICU) at the enrollment day
 ,the third, seventh, and fourteen days after enrollment or until ICU discharge (whatever come
 first). Total DNA from the nasal and fecal specimens will be extracted, amplified, and
 sequenced to determined the characteristics of gut microbiota and nasal microbiota. Finally,
 the characteristics of gut microbiota and nasal microbiota combined clinical information will
 be used to construct a prediction model to predict the prognosis of sepsis.

ICD-10 classifications
Septic shockOther sepsisOther specified sepsisSepsis, unspecifiedSepsis due to other specified staphylococcus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05143736
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05143736 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhujiang Hospital and is currently Recruiting. The study focuses on Sepsis,Septic Shock. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.